切换至 "中华医学电子期刊资源库"

中华临床实验室管理电子杂志 ›› 2016, Vol. 04 ›› Issue (01) : 13 -17. doi: 10.3877/cma.j.jssn.2095-5820.2016.01.004

所属专题: 文献

综述

肿瘤靶向药物相关受体研究进展
胡敏1,(), 王继贵1   
  1. 1. 410011 长沙,中南大学湘雅二医院检验科
  • 收稿日期:2015-10-22 出版日期:2016-02-28
  • 通信作者: 胡敏

Investigating progress on targeted anticancer therapy

Min Hu1,(), Jigui Wang1   

  1. 1. Department of Clinical Laboratory, the Second Xiangya Hospital of Central South University, Changsha 410011, China
  • Received:2015-10-22 Published:2016-02-28
  • Corresponding author: Min Hu
  • About author:
    Corresponding author: Hu Min, Email:
引用本文:

胡敏, 王继贵. 肿瘤靶向药物相关受体研究进展[J/OL]. 中华临床实验室管理电子杂志, 2016, 04(01): 13-17.

Min Hu, Jigui Wang. Investigating progress on targeted anticancer therapy[J/OL]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2016, 04(01): 13-17.

对癌细胞及其组织靶向给予抗癌药物是临床治疗癌症的新手段,当细胞毒化疗剂(如紫杉醇和阿霉素)有效杀死癌细胞时,它们并不能区分癌细胞和正常细胞;当患者需要根除肿瘤大剂量使用细胞毒剂药物时,这种非针对性的特异性选择将导致患者全身毒性不良反应,从而造成患者非肿瘤部位组织和功能损伤。本文主要针对靶向药物在肿瘤微环境过表达受体的作用机制,及7种相关受体分子的结构和功能特点进行阐述。

Targeted delivery of anticancer drugs to cancer cells and tissues is a promising field. While cytotoxic chemotherapeutic agents such as paelitaxel and doxorubicin effectively kill cancer cells, they cannot distinguish cancer cells from normal cells, the lack of selectivity will cause systematic toxicity to patients when they are exposed to the high dosages of cytotoxic agents required to eradicate the tumor. This article focuses on overexpressed receptors exploited for targeting drugs to cancer and the tumor microenvironment, and briefly evaluates the structure and function of these receptor molecules.

1
Sutcliffe SB. Cancer control:life and death in an unegual world [J]. Curr Oncol, 2012,19(1):12-15.
2
Zwanziger D, Beck-Sickinger AG. Radiometal targeted tumour diagnosis and therapy with peptide hormones [J]. Curr Pharm Des, 2008,14(24):2385-2400.
3
Sancho V, Di Florio A, Moody TW, et al. Bombesin receptor mediated imaging and cytotoxicity:review and current status[J]. Curr Drug Deliv, 2011,8(1):79-134.
4
Majumdar ID, Weber HC. Biology of mammalian bombesin-like peptides and their receptors [J]. Curr Opin Endocrinol Diabetes Obes, 2011,18(1):68-74.
5
Sun LC, Coy DH. Somatostatim receptor-targeted anti-cancer therapy[J]. Curr Drug Deliv, 2011,8(1):2-10.
6
Asundi J, Reed C, Arca J, et al. An antibody-drug conjugate targeting the endothelin B receptor for the tretment of melanoma [J]. Clin Cancer Res, 2011,17(5):965-975.
7
Desrosellier JS, Cheresh DA. Integrins in cancer:biological implications and therapeutic opportunities [J]. Nat Rev Cancer, 2010, 10(1):9-22.
8
zhan C, Gu B, Xie C, et al. Cyclic RGD conjugated poly(ethylene glycol)-co-poly(lactic acid)micell enhances paclitaxel anti-glioblastoma effect [J]. J Control Release, 2010,143(1):136-142.
9
Xiao K, Li Y, Lee JS, et al. OA02 peptide facilitates the precise targetimg of pacitaxel-loaded micellar nanoparticles to ovarian in vivo [J]. Cancer Res, 2012, 72(8):2100-2110.
10
Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors [J]. Nature, 2013,500(7463):486-489.
11
Muller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptor positive cancer [J]. J Nucl Med, 2011,52(1):1-4.
12
Liu X, Ma S, Dai C, et al. Antiprolifeative, antiinvasive,and proapoptotic activity of folate receptor α-targeted liposomal DOX in nonfunctional pituitary adenoma cells [J]. Endocrinology, 2013,154(4):1414-1423.
13
Dufes C, AI Robaian M, Somani C. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells [J]. Ther Deliv, 2013,4(5):629-640.
14
Han CY, Yue LL, Tai LY, et al. A novel small peptide as an epidermal growth factor receptor targeting ligand for nanodelivery in vitro [J]. Int J Nanomedicine, 2013,8:1541-1549.
15
Xiao W, Chen X, Yang L, et al. co-delivery of DOX and plasmid by a novel FGFR-mediated cationic liposome [J]. Int J Pharm, 2010,393(1-2):119-126.
16
Spitzer D, Simon PO Jr, Kashiwagi H, et al. Use of multifunctionakl sigma-2 receptor ligand conjugated to trigger cancer selective cell death signaling [J]. Cancer Res, 2012,72(1):201-209.
[1] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[2] 张启龙, 柳亿, 卢会丽, 罗慧, 李成林, 王菁, 王辉. 奥妥珠单抗治疗磷脂酶A2受体相关膜性肾病的疗效与安全性:单中心回顾性分析[J/OL]. 中华危重症医学杂志(电子版), 2024, 17(05): 379-384.
[3] 刘琴, 刘瀚旻, 谢亮. 基质金属蛋白酶在儿童哮喘发生机制中作用的研究现状[J/OL]. 中华妇幼临床医学杂志(电子版), 2024, 20(05): 564-568.
[4] 笪东祝, 林凯, 王小蕊, 王开银, 王敏, 王玮, 李瑾, 刘俊. 低促甲状腺激素水平结节性甲状腺肿的发生发展与促甲状腺激素受体基因D727E 多态性的相关性研究[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 443-446.
[5] 黄福, 王黔, 金相任, 唐云川. VEGFR2、miR-27a-5p在胃癌组织中的表达与临床病理参数及预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 558-561.
[6] 胡思平, 熊性宇, 徐航, 杨璐. 衰老相关分泌表型因子在前列腺癌发生发展中的作用机制[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 425-434.
[7] 郑俊, 吴杰英, 谭海波, 郑安全, 李腾成. EGFR-MEK-TZ三联合分子的构建及其对去势抵抗性前列腺癌细胞增殖与凋亡的影响[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(05): 503-508.
[8] 赖淼, 景鑫, 李桂珍, 李怡. 非小细胞肺癌EGFR 突变亚型的临床病理和预后意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 731-737.
[9] 梁丽斯, 李洁, 贺帅, 来艳君, 刘铭, 张琳. MMP-9、MMP-2 及TLR4、HE4对非小细胞肺癌早期诊断意义[J/OL]. 中华肺部疾病杂志(电子版), 2024, 17(05): 756-761.
[10] 刘先勇, 秦东梅, 张若梅, 李俊娇, 孟春芹, 邬明歆, 王玉红, 赵新鲜, 徐瑞联, 洪文文, 马玲, 仇玮, 周宇. Her2/Hes1在肠型胃癌Correa级联反应3个病理阶段中的表达及意义[J/OL]. 中华细胞与干细胞杂志(电子版), 2024, 14(06): 321-327.
[11] 陈伟杰, 何小东. 胆囊癌免疫靶向治疗进展[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 763-768.
[12] 魏妙艳, 徐近. 合并远处转移胰腺癌系统性治疗的梳理和展望[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 644-650.
[13] 张英信, 林婷, 张剑文. 构建靶向HLA-A2且表达PD-L1的CAR-Treg细胞及验证其对CD4+T细胞抑制作用[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(05): 719-728.
[14] 吴东阳, 林向丹, 石佐林, 赵玉龙, 王振, 文安国, 纪鑫, 李俊之, 赵明光. NF-L、NLRP3、S100B 蛋白在颅脑损伤严重程度及预后评估中的应用价值[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 279-285.
[15] 李润东, 豆小文, 张秀明. 失笑散联合胃复春治疗慢性萎缩性胃炎的疗效及对血清免疫受体和炎症因子水平的影响[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 470-473.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?